Raymond James Maintains Strong Buy on ADMA Biologics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Elliot Wilbur maintains a Strong Buy rating on ADMA Biologics and increases the price target from $8 to $10.
May 10, 2024 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James analyst Elliot Wilbur has reaffirmed a Strong Buy rating on ADMA Biologics and raised the price target from $8 to $10, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst firm like Raymond James typically signals a strong conviction in the company's future performance. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100